Molecule Name |
DB11618
|
DrugBank Groups |
Experimental
|
Cluster No |
173
|
Smiles |
O=C5(C4(=C(O)C2(=C(CC(O)(C(=NN=C(O)C1(=CC=CC=C1))C)CC2OC3(OC(C(O)C(C3)N)C))C(=C4C(=O)C=6(C5=C(OC)C=CC=6))O)))
|
Download |
mol2, pdbqt
|
TPSA |
454,96
|
Non-H Atoms |
47
|
Non-C/H Atoms |
13
|
Metal-Atoms |
0
|
Electronegative Atoms |
13
|
Stereo Centers |
6
|
Rotatable Bonds |
6
|
Rings Closures |
6
|
Small Rings |
6
|
Aromatic Rings |
3
|
Aromatic Atoms |
18
|
sp3-Atoms |
21
|
Symmetric atoms |
2
|
cLogS |
-6,895
|
MW |
645,663
|
cLogP |
3,8385
|
HBA |
13
|
HBD |
6
|
Ro5 violations |
3
|
Druglikeness |
6,7592
|
DrugScore |
0,171440489803693
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
high
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA-
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,4894
|
Caco-2 Permeability 2 |
-0,2142
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
1,0802
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,5661
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,8645
|
Carcinogenicity (Three-class) |
Non-required
|